Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance by Joen Sveistrup et al.
Sveistrup et al. Radiation Oncology 2014, 9:44
http://www.ro-journal.com/content/9/1/44RESEARCH Open AccessImprovement in toxicity in high risk prostate
cancer patients treated with image-guided
intensity-modulated radiotherapy compared to
3D conformal radiotherapy without daily image
guidance
Joen Sveistrup1*, Per Munck af Rosenschöld1, Joseph O Deasy2, Jung Hun Oh2, Tobias Pommer1,
Peter Meidahl Petersen3 and Svend Aage Engelholm1Abstract
Background: Image-guided radiotherapy (IGRT) facilitates the delivery of a very precise radiation dose. In this study
we compare the toxicity and biochemical progression-free survival between patients treated with daily image-
guided intensity-modulated radiotherapy (IG-IMRT) and 3D conformal radiotherapy (3DCRT) without daily image
guidance for high risk prostate cancer (PCa).
Methods: A total of 503 high risk PCa patients treated with radiotherapy (RT) and endocrine treatment between
2000 and 2010 were retrospectively reviewed. 115 patients were treated with 3DCRT, and 388 patients were treated
with IG-IMRT. 3DCRT patients were treated to 76 Gy and without daily image guidance and with 1–2 cm PTV
margins. IG-IMRT patients were treated to 78 Gy based on daily image guidance of fiducial markers, and the PTV
margins were 5–7 mm. Furthermore, the dose-volume constraints to both the rectum and bladder were changed
with the introduction of IG-IMRT.
Results: The 2-year actuarial likelihood of developing grade > = 2 GI toxicity following RT was 57.3% in 3DCRT
patients and 5.8% in IG-IMRT patients (p < 0.001). For GU toxicity the numbers were 41.8% and 29.7%, respectively
(p = 0.011). On multivariate analysis, 3DCRT was associated with a significantly increased risk of developing grade > = 2
GI toxicity compared to IG-IMRT (p < 0.001, HR = 11.59 [CI: 6.67-20.14]). 3DCRT was also associated with an increased risk
of developing GU toxicity compared to IG-IMRT.
The 3-year actuarial biochemical progression-free survival probability was 86.0% for 3DCRT and 90.3% for IG-IMRT
(p = 0.386). On multivariate analysis there was no difference in biochemical progression-free survival between 3DCRT
and IG-IMRT.
Conclusion: The difference in toxicity can be attributed to the combination of the IMRT technique with reduced dose
to organs-at-risk, daily image guidance and margin reduction.
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Table 1 Patient characteristics
Categorical
characteristic
3DCRT n = 115 IG-IMRT n = 388 P value
No patients (%) No patients (%)
Performance status 0.180
0 110 (96) 367 (95)
1 5 (4) 21 (5)
Comorbidity* 0.070
Yes 66 (60) 215 (56)
No 44 (40) 166 (44)
Smoking# 0.091
Yes 30 (32) 106 (29)
No 65 (68) 255 (71)
T-stage 0.190
≤T2a 19 (17) 96 (25)
T2b 3 (2) 10 (2)
≥T2c 92 (81) 281 (73)
Gleason score <0.001
5-6 42 (44) 49 (13)
7 21 (22) 197 (51)
8-10 33 (34) 141 (36)
Adjuvant ADT 0.019
Yes 72 (88) 350 (95)
No 10 (12) 20 (5)
Type of ADT 0.054
GnRH agonist 100 (89) 365 (95)
Antiandrogen 12 (11) 21 (5)
Continuous
characteristic
Median (range) Median (range) P value
Age (y) 63 (52–75) 66 (49–76) <0.001
PSA (ng/ml) 32.7 (4.2-150) 24.9 (4.2-200) <0.001
PPB† (%) 75 (17–100) 67 (5–100) 0.006
Follow-up (yr) 8.2 (0.1-12.5) 3.5 (0.3-7.1) <0.001
*Any comorbidity at the time of diagnosis.
#Smoking at the time of diagnosis.
†Percentage of positive (malignant) biopsies.
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Radiotherapy in combination with androgen-deprivation
therapy (ADT) is a well-documented treatment option
for high risk prostate cancer (PCa) [1]. With intensity
modulated radiotherapy (IMRT) it is possible to deliver
high doses to the target and at the same time reduce the
dose to the surrounding normal tissue [2]. Recently, the
concept of image guided radiotherapy (IGRT) has been
introduced in the treatment of PCa. IGRT is often based
on the implantation of fiducial gold markers in the
prostate. With markers implanted in the prostate, the
position of the prostate can be verified before each treat-
ment fraction using portal imaging. This limits the inter-
fractional variability in the position of the prostate and
as a consequence the PTV margins can be reduced [3].
In theory, a reduction in PTV margins should reduce
the dose to the organs at risk and consequently result in
less toxicity [4]. However, there is concern that large
margin reductions might increase the risk of geograph-
ical miss of the target, which might result in higher rates
of local failure [5].
In our centre, the RT for PCa has changed during the
past decade. In 2000–2005 patients were treated with
3D conformal radiotherapy (3DCRT) to 76 Gy and without
daily image guidance. In 2005, we introduced daily image-
guided intensity modulated radiotherapy (IG-IMRT) based
on implanted markers in the prostate. With the introduc-
tion of IG-IMRT, the PTV margins were reduced substan-
tially, and the dose was increased to 78 Gy.
The purpose of this study is to compare toxicity and
biochemical progression-free survival between patients
treated with IG-IMRT and 3DCRT for high risk PCa.
We hypothesize that IG-IMRT and reduced margins re-
sult in less toxicity compared to 3DCRT with broader
margins and without daily image guidance. On the other
hand, given the accuracy of IGRT the reduction in mar-




A total of 503 high risk PCa [6] patients treated with
radiotherapy (RT) in the Department of Radiation
Oncology at Rigshospitalet, Copenhagen, Denmark be-
tween January 1st 2000 and December 31 2010 were
retrospectively reviewed. The definition of high risk dis-
ease was based on the d’Amico classification and was
characterized by a T-stage ≥ T2c or Gleason Score ≥8 or
Prostate Specific Antigene (PSA) level >20 ng/ml.
Between 2000–2005, 115 patients were treated with
3DCRT to 76 Gy without daily image guidance. Between
2005–2010, 388 patients were treated with IG-IMRT to
78 Gy. The large difference in the number of patients in
the two cohorts can be explained largely by increasedreferral due to both increasing incidence of PCa as well
as higher acceptance of RT as a relevant therapy for
PCa. Pelvic node irradiation was not used in any of the
patients.
The diagnosis of PCa was based on either transrectal
ultrasound (TRUS) with biopsies or transurethral resec-
tion of the prostate (TUR-P). Histopathological samples
were centrally reviewed. Patients were staged according to
the American Joint Committee on Cancer staging system.
There were no signs of lymph node metastases or distant
metastases. Patient characteristics are shown in Table 1.
Comorbidity was present in 281 patients (56%). The
five most common comorbidities were hypertension (95
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(35 patients), diabetes (28 patients) and chronic ob-
structive pulmonary disease or asthma (28 patients). The
majority of patients with comorbidity had more than
one comorbidity.
Androgen deprivation therapy (ADT) guidelines were
the same for the entire cohort. The ADT consisted of
3 months of neo-adjuvant treatment followed by two
years of adjuvant treatment with primarily a GnRH
(Gonadotropin releasing hormone) agonist combined
with an antiandrogen in 30 days to account for the flare
reaction. Alternatively, an antiandrogen was used as
monotherapy during the whole ADT. Only two patients
(one in the 3DCRT and one in the IG-IMRT group) did
not receive neo-adjuvant ADT. A total of 30 patients
did not receive adjuvant ADT.
Follow-up evaluations were performed in the Depart-
ments of Urology at either 3 or 6 months intervals.
Genitourinary (GU) and gastrointestinal (GI) toxicity were
assessed retrospectively based on patient records and was
reported at the end of the RT, and at 6, 12 and 24 months
after RT. The grading of toxicity was based on the Com-
mon Terminology Criteria for Adverse Events (CTC ver-
sion 4.0) and was performed by a single physician (JS).
GI toxicity included diarrhea, rectal hemorrhage, rectal
pain and rectal incontinence. GU toxicity included dys-
uria, pollakisuria, incontinence, bladder spasms, hematuria,
urinary retention or non-specified symptoms. Erectile dys-
function was not reported in this study due to very low
reporting in the patient records. Furthermore, the majority
of patients received two years of adjuvant ADT.
Biochemical progression was based on the Phoenix def-
inition, i.e. a rise in PSA by 2 ng/mL or more above the
nadir PSA level [7]. In case salvage ADT was commenced
due to PSA progression before relapse according to the
Phoenix definition, the date of the start of salvage ADT
was defined as the date of biochemical progression.
Approval from the National Ethics Committee was
not needed since this was a retrospective study, which
had no influence on the treatment of the patients. The




3DCRT was delivered using the BeamCath® technique, see
[8] for full details. Briefly, the BeamCath is a special ureth-
ral catheter containing high-density fiducial markers and
it was placed in the patient’s urethra and bladder. The
markers can be visualized using electronic portal vision
device (Varian Medical Systems, Palo Alto, US) and allows
for better vizualisation of the urethral part of the prostate.
The catheter was used during the treatment planning pro-
cedure and then only during the first 3 fractions. Theplanning target volume (PTV) for the first 3 fractions
included the prostate with no margin using two oppos-
ing lateral photon beams of 18 MV, shielding the rec-
tum. Thus, the BeamCath technique allows the dose to
be escalated from 70 Gy to 76 Gy without an increase
in toxicity [9].
The remaining treatment was delivered without the
BeamCath using a standard 4-field box technique with
weekly port film verification based on bony landmarks.
The clinical target volume (CTV) was defined as the
prostate visible on CT. The seminal vesicles (SM) were
included in the target if the risk of involvement exceeded
10% according to Partin’s Nomogram [10], or if SM bi-
opsies showed malignant involvement. Fourth and
fifth fractions were delivered with a margin to the
PTV of 1 cm and the remaining 33 fractions with a
margin of 2 cm. Treatment plans were made based on
ICRU (International Commission of Radiation Unit
and Measurement) guidelines with a dose variation of
95 to 107% within the PTV. The prescription dose was
76 Gy (2 Gy per fraction, 5 fractions per Week).
Dose volume constraints were as follows: Less than 20%
of the outlined rectal volume should receive doses >70 Gy.
For the bladder, the mean dose should not exceed 80% of
the dose to the ICRU reference point, i.e. 60.8 Gy.
IG-IMRT (years 2005–2010)
IMRT was delivered with a 5-beam sliding window tech-
nique (fixed-angle IMRT) in the years 2005–2008 and with
a single beam rotational technique (VMAT - RapidArc®,
Varian Medical Systems, Palo Alto, US) in the years 2008–
2010; see [11] for full details. Fixed-angle IMRT was used
in 236 patients and VMAT was used in 152 patients.
Before RT planning, three gold fiducial markers were
placed in the prostate under ultrasound guidance. Patients
were subsequently scanned using CT and MR (1.5 T and
T1 and T2 weighted imaging) in the supine treatment
position. MR and CT data sets were exported and manu-
ally matched using the gold markers as reference. Bladder,
rectum, femoral heads and prostate were defined using
MR/CT. The treatment position was verified daily before
treatment based on the implanted markers using orthog-
onal stereoscopic kilovoltage x-ray images (ExacTrac®,
BrainLab AG, Germany) and digitally reconstructed radio-
graphs from the simulation CT.
The CTV was defined as the prostate and any extra-
prostatic tumor visible on MR. The two proximal cm of
the SM were included in the CTV, if the risk of involve-
ment exceeded 10% according to Partin’s Nomogram
[10]. In case SM biopsies showed malignant involve-
ment, the entire SM was included in the CTV. The PTV
margin was 5 mm in the right-left and anterior-posterior
planes and 7 mm in the superior-inferior plane. Image
registrations and plans were made using the Eclipse
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Palo Alto, CA, US) and based on ICRU guidelines. The
prescription dose was 78 Gy (2 Gy per fraction, 5 frac-
tions per week).
The dose-volume constraints were as follows: For the
rectum, less than 60% of the volume received 40 Gy, less
than 50% received 50 Gy and less than 10% of the vol-
ume received 70 Gy. For the bladder, less than 50% of
the volume received 50 Gy.
Statistical analysis
The patient characteristics in the two groups were com-
pared using a Chi-square test or a Fischer’s exact test for
categorical variables and an independent sample t-test
or the Mann–Whitney test for continuous variables.
The Kaplan Meier method was used to calculate the
2-year actuarial probability of developing ≥2 grade GI
and GU toxicity. The same test was used to calculate
the 3-year actuarial biochemical progression-free sur-
vival probability.
A Cox regression analysis was used to identify predictors
of developing grade ≥2 GI and GU toxicity and biochem-
ical progression. The following covariates were applied in
the Cox regression analyses of toxicity: Age, performance
status (PS), comorbidity, smoking, treatment technique
(3DCRT vs IG-IMRT), and the use of ADT. In the cox re-
gression analysis of biochemical progression the T-stage,
percentage of positive (malignant) biopsies (PPB), Gleason
score and PSA level were furthermore included.
Age, PPB, Gleason score and PSA were treated as con-
tinuous variables and the remaining as categorical variables.
Results
The 2-year actuarial likelihood of developing grade ≥2
GI toxicity following RT was 57.3% for 3DCRT andFigure 1 Comparison of the actuarial likelihood of developing a grad
between patients treated with 3DCRT and IG-IMRT.5.8% for IG-IMRT (p < 0.001). For grade ≥2 GU tox-
icity the corresponding numbers were 41.8% and 29.7%
(p = 0.011), respectively (Figure 1).
Predictors of toxicity and biochemical progression are
shown in Tables 2 and 3, respectively. For the continuous
variables age, PPB, Gleason score and PSA, the results in-
dicate the hazard ratio per one unit increase in the vari-
ables. For PS the results indicate the hazard ratio for
patients with PS = 1 compared to patients with PS = 0.
For the T-stage the results indicate the hazard ratio for
patients with T-stage ≥ T2c compared to patients with
T-stage ≤ T2b.
In the multivariate analysis, 3DCRT was associated
with a significantly increased risk of developing grade ≥2
GI toxicity compared to the IG-IMRT group (p < 0.001,
HR = 11.59 [CI: 6.67-20.14]). 3DCRT was also associated
with a significantly increased risk of developing grade ≥2
GU toxicity compared to IG-IMRT (p = 0.015, HR = 1.72
[CI:1.11-2.67]). Furthermore, patients with comorbidity
had a higher risk of developing GU toxicity compared
to patients without comorbidity (p = 0.038, HR = 1.50
[CI:1.02-2.21]). Finally, the use of ADT was protective
of GI toxicity (p < 0.001, HR = 0.23 [CI: 0.10-0.50]).
The 3-year actuarial biochemical progression-free
survival probability was 86.0% for 3DCRT and 90.3%
for IG-IMRT (p = 0.386) (Figure 2). As shown in the
Cox regression analysis in Table 3, there was no signifi-
cant difference between 3DCRT and IG-IMRT in the
risk of developing biochemical progression (p = 0.505,
HR = 0.78 [CI:0.37-1.57]). Increasing age was associated
with a lower risk of developing biochemical progression
(p = 0.017, HR = 0.93 [CI: 0.88-0.99]). Higher percent-
age of positive (malignant) biopsies (PPB) was predict-
ive of biochemical progression (p = 0.038, HR = 1.01
[CI: 1.00-1.02]).e ≥2 GI and GU toxicity, respectively, during a 2-year follow-up
Table 2 Univariate and multivariate analyses of grade +2 GI and GU toxicity
GI Toxicity Univariate analysis Multivariate analysis
Parameter Hz 95% CI p-value Hz 95% CI p-value
Age 0.93 0.89-0.97 <0.001* 0.99 0.93-1.04 0.584
Performance status 1.67 0.73-3.85 0.227 1.84 0.70-4.82 0.218
Comorbidity 1.18 0.75-1.86 0.482 0.88 0.62-1.77 0.878
Smoking 1.05 0.62-1.77 0.853 0.71 0.51-1.58 0.708
3DCRT vs IG-IMRT 12.81 7.84-20.92 <0.001* 11.59 6.67-20.14 <0.001*
Adjuvant ADT 0.31 0.16-0.60 0.001* 0.27 0.13-0.56 <0.001*
GU toxicity Univariate analysis Multivariate analysis
Parameter Hz 95% CI p-value Hz 95% CI p-value
Age 1.00 0.97-1.04 0.869 1.01 0.97-1.05 0.476
Performance status 1.80 0.99-3.24 0.052 1.68 0.89-3.18 0.111
Comorbidity 1.50 1.07-2.11 0.018* 1.50 1.02-2.21 0.038*
Smoking 1.27 0.89-1.81 0.185 1.28 0.88-1.88 0.200
3DCRT vs IG-IMRT 1.58 1.10-2.26 0.013* 1.72 1.11-2.67 0.015*
Adjuvant ADT 0.60 0.34-1.06 0.078 0.57 0.30-1.06 0.075
*Statistically significant.
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In this study, we compared toxicity and biochemical
progression-free survival in high risk PCa patients
treated with either of two RT techniques: 3DCRT with-
out daily image guidance versus daily fiducial-based IG-
IMRT. IG-IMRT was introduced in our centre in 2005
and was accompanied by a small dose escalation and a
substantial reduction in PTV margins. To our know-
ledge, this is one of the largest studies to demonstrate
the clinical effect of introducing IG-IMRT and smaller
margins in the treatment of high risk PCa. In lack of
randomized trials comparing RT techniques and differ-
ent margins, it is important that we keep reportingTable 3 Univariate and multivariate analyses of biochemical p
Univariate analysis
Parameter Hz 95% CI
Age 0.93 0.90-0.97
Performance status 0.57 0.14-2.32
Comorbidity 1.02 0.66-1.58
Smoking 1.15 0.71-1.88
T-stage (≥T2c vs≤ T2b) 0.71 0.44-1-16
PPB# 1.02 1.01-1.03
Gleason score 1.29 1.05-1.58
PSA 1.00 1.00-1.01
3DCRT vs IG-IMRT 1.24 0.77-2.00
Adjuvant ADT 0.59 0.28-1.24
*Statistically significant.
#Percentage positive biopsies.clinical outcomes following the implementation of new
radiation techniques [12].
We found that 3DCRT patients experienced signifi-
cantly more toxicity than IG-IMRT patients. The ob-
served difference in GI toxicity was large and can be
attributed to the combination of the accuracy of IGRT,
reduced PTV margins and IMRT-based dose sparing of
the rectum [4,13]. Furthermore, the use of MR imaging
in the treatment planning of IG-IMRT probably results
in reduced dose delivery to the organs at risk due to
smaller clinical target volumes [14]. We speculate that
the major contributing factor for the large difference in
GI toxicity is the large difference in PTV marginsrogression
Multivariate analysis
p-value Hz 95% CI p-value
0.001* 0.93 0.88-0.99 0.017*
0.432 0.40 0.05-2.93 0.371
0.931 1.03 0.56-1.82 0.928
0.574 1.31 0.73-2.35 0.361
0.170 0.58 0.29-1.17 0.128
0.001* 1.01 1.00-1.02 0.038*
0.014* 1.04 0.80-1.39 0.759
0.555 1.00 0.99-1.01 0.433
0.386 0.78 0.37-1.57 0.505
0.163 0.89 0.31-2.56 0.830
Figure 2 Comparison of the actuarial likelihood of developing
biochemical relapse between patients treated with 3DCRT
and IG-IMRT.
Sveistrup et al. Radiation Oncology 2014, 9:44 Page 6 of 8
http://www.ro-journal.com/content/9/1/44between the two groups. An example of a 3DCRT plan
with 2 cm PTV margin and a fixed-angle IMRT plan
with 5–7 mm PTV margins is shown in Figure 3. As-
sessment of the differences in dose-volume parameters
between the treatment groups was beyond the scope of
this clinical report.
Compared to other studies of non-image guided
3DCRT, we observed a relatively high degree of GI tox-
icity in our 3DCRT patients. However, our results are
comparable to other reports of 3DCRT using the Beam-
Cath technique [9,15]. Furthermore, the 2 cm PTV mar-
gin used in most fractions in 3DCRT is wider than what
is commonly used in studies of 3DCRT without daily
image guidance. The difference in GU toxicity between
the two treatment groups was not nearly as significant
as the difference in GI toxicity. A part of the explanation
might be that the prostatic part of the urethra was notFigure 3 Left: Treatment plan for 3DCRT (2 cm PTV margin). Right: Trspared in either of the treatment groups [16]. Not sur-
prisingly, patients with comorbidity seemed to have a
higher risk of developing GU toxicity compared to pa-
tients without comorbidity.
Even though the entire cohort consisted of high risk
patients, 30 patients did not receive adjuvant ADT.
Interestingly, we found that the use of adjuvant ADT
was independently associated with a lower risk of devel-
oping GI toxicity. Although short-term ADT has previ-
ously been shown to be protective of toxicity [17], the
actual mechanism of such an effect remains unclear.
There was no significant difference in biochemical
progression-free survival between the two treatment
groups. The minor difference in prescribed dose was not
expected to influence the biochemical progression-free
survival to a large degree [18]. The major difference be-
tween the two groups besides the actual radiation tech-
nique was the use of daily image guidance and the size
of the PTV margins. The 2 cm margin used in the ma-
jority of fractions with 3DCRT should be large enough
to account for the interfractional and intrafractional mo-
tion of the prostate [19]. With the introduction of IG-
IMRT, the margins were reduced to 5–7 mm due to
higher accuracy of the dose delivery [20]. As mentioned
in the introduction, concern has been raised that IGRT
and a large reduction in PTV margins might lead to
higher rates of local failure. Engels et al. [5] found that
IGRT with 3–5 mm margins was associated with a
poorer biochemical progression-free survival in patients
treated with conformal arc therapy compared to non-
IGRT and 6–10 mm margins. Our results are reassuring
in that the substantial margin reduction from 2 cm to
5–7 mm did not seem to compromise the biochemical
progression-free survival in IG-IMRT patients.
Both 3DCRT to 76 Gy and IG-IMRT to 78 Gy resulted
in excellent tumor control. Our results are consistent
with the results from other reports of high risk PCa
[4,21]. The percentage of positive biopsies (PPB) was an
independent predictor of biochemical progression. It
would be easily understood if PPB were a more accurate
marker of tumor advancement than the clinical T-stage,eatment plan for fixed-angle IMRT (5–7 mm PTV margin).
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ability. Increasing age was associated with a significantly
lower risk of biochemical relapse, which might reflect
that younger patients might have more aggressive tu-
mors [22].
This study has several limitations. First of all, retro-
spective assessment of toxicity based on patient records
involves a substantial degree of uncertainty. It is also a
limitation that 13 of 41 of the relapses in the 3DCRT co-
hort were based on the initiation of salvage ADT due to
PSA progression before relapse according to the Phoenix
definition. This might falsely lower the biochemical
progression-free survival in the 3DCRT group compared
to the IG-IMRT group in which all relapses were based
on the Phoenix definition. The two cohorts also differed
significantly in baseline characteristics, which might
affect the risk of biochemical progression differently in
the two groups. Finally, as the median length of follow-
up was relatively short in the IG-IMRT group, we were
only able to report the 3-year biochemical progression-
free survival rates. Thus, our results are somewhat prema-
ture, also considering that the large majority of patients
received two years of adjuvant ADT.
Conclusion
In this study, the combination of daily image guidance,
IMRT and 5–7 mm PTV margins to 78 Gy resulted in
significantly reduced GI and GU toxicity compared to
3DCRT to 76 Gy without daily image guidance and with
1–2 cm PTV margins. Importantly, the large reduction
in margins did not seem to affect the level of biochem-
ical tumor control in IG-IMRT patients. A major caveat
is that this improvement may depend on the details of
our implementation, and this should not be taken as a
broad confirmation that any implementation of IG-
IMRT with reduced margins is always an improvement
over 3DCRT with larger margins.
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